Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020147 | 1.00 | MAOB (0.62) | MAOBALOX5MAOARXRARXRB | |
| SCHEMBL7396817 | 0.87 | MAOB (0.60) | MAOBALOX5MAOARXRARXRB | |
| SCHEMBL9131943 | 0.87 | MAOB (0.60) | MAOBALOX5MAOARXRARXRB | |
| SCHEMBL9129876 | 0.86 | MAOB (0.71) | MAOBMAOA | |
| SCHEMBL7396562 | 0.86 | MAOB (0.71) | MAOBMAOA | |
| SCHEMBL1071203 | 0.86 | MAOB (0.58) | MAOBALOX5MAOAFFAR1 | |
| SCHEMBL8935317 | 0.83 | ALOX5 (0.62) | MAOBALOX5MAOARXRARXRB | |
| SCHEMBL9516428 | 0.82 | MAOB (0.53) | MAOBALOX5MAOAFFAR1 | |
| SCHEMBL9126134 | 0.82 | MAOB (0.53) | MAOBALOX5MAOAFFAR1 | |
| SCHEMBL2017533 | 0.81 | ALOX5 (0.63) | MAOBALOX5MAOARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160308-A1 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders | ALCON RESEARCH, LTD. (US) | 2011-06-30 | — | — | US | disclosed |
| CN-101495185-A | Monoamine oxidase inhibitors for the treatment of disorders of the outer retina | ALCON RES LTD (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-0400495-B1 | N-phenylalkyl substituted alpha-amino carboxamide derivatives and process for their preparation. | ERBA CARLO SPA (IT) | 1993-11-03 | — | — | EP | disclosed |
| EP-0426816-A1 | N-PHENYLALKYL SUBSTITUTED $g(a)-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-05-15 | — | — | EP | disclosed |
| EP-0400495-A1 | N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-12-05 | — | — | EP | disclosed |
| WO-1990014334-A1 | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160308-A1 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders | MAOB, MAOA, ALDH1A2 | MAOB 1/4885ALOX5 397/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.